Guardant Health, Inc. has disclosed a recent transaction involving restricted stock units by Kevin R. Sayer, a director at the company. This filing is significant as it highlights the company's approach to executive compensation and aligns with shareholder interests.
Background
Guardant Health, Inc., identified by the Central Index Key 0001576280, operates in the medical laboratories sector (SIC: 8071). The company is publicly traded on the Nasdaq under the ticker symbol GH. It is classified as a large accelerated filer and is headquartered in Palo Alto, California.
What the Filing Says
According to the filing dated November 13, 2026, Kevin R. Sayer reported the acquisition of 3,149 restricted stock units on November 9, 2026. These units will vest over a three-year period, with one-third becoming available on November 2, 2027, and the remaining shares vesting annually thereafter.
Impact
This transaction may affect shareholders’ views on executive compensation at Guardant Health. As a director, Sayer's decisions and compensation structure could influence the company's strategic direction and operational performance. Other companies in the medical laboratories sector may also take note of this transaction as they evaluate their own compensation practices.
What's Next
The filing does not say what happens next.
Details of the Transaction
The filing indicates that the restricted stock units acquired by Kevin R. Sayer are set to vest in a staggered manner, with one-third of the units vesting on November 2, 2027, and the remaining two-thirds vesting annually over the subsequent two years. This structure is designed to incentivize long-term performance and retention of key executives.
Ownership Following the Transaction
Post-transaction, Kevin R. Sayer holds a total of 3,149 shares of common stock, which reflects his direct ownership following the acquisition of the restricted stock units. This ownership structure is critical as it aligns his interests with those of the shareholders, potentially enhancing his commitment to the company's success.
Signatory Information
The filing was signed by John G. Saia, acting as attorney-in-fact for Kevin R. Sayer, on November 12, 2026. This indicates that Sayer may have designated Saia to handle certain filing responsibilities on his behalf, which is a common practice in corporate governance.
Additional Context
While the filing provides insights into the specific transaction and ownership details, it does not include any information regarding the overall compensation package for Kevin R. Sayer or how this transaction fits into the broader strategy of Guardant Health, Inc. Additionally, there are no details regarding the company's performance metrics that may influence future vesting or compensation decisions.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




